Home » Authors » Karl Thiel

Karl Thiel

Articles

ARTICLES

The Best and Worst of Biotech in 2008

Jan. 5, 2009

New Washington Alignments Bring Period of Uncertainty

Dec. 1, 2008

How Biotech Can Make Even Cash Look Bad

Nov. 3, 2008

Has the Economic Mess Diluted Biotech's Hand?

Sep. 29, 2008

Good News from Capital Markets: Some VCs Taking a Long View

Sep. 2, 2008

Are Biotechs Build to Prosper or Are They Built to be Sold?

Aug. 4, 2008

Two-Year DTC Ad Moratorium Weakens Patient Education Role

June 30, 2008

Election 2008: Say Hail to the Chief of Scientific Illiteracy

June 2, 2008

Japan Pharmas' Love for U.S. Biotechs Just Heating Up

April 28, 2008

The FDA is Treading Water Until a True Leader Arrives

March 31, 2008

View All Articles by Karl Thiel

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...